|
1
|
Golob-Schwarzl N, Krassnig S, Toeglhofer
AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H,
Schicho R, Fickert P, et al: New liver cancer biomarkers:
PI3K/AKT/mTOR pathway members and eukaryotic translation initiation
factors. Eur J Cancer. 83:56–70. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang H, Song Y, Yang H, Liu Z, Gao L,
Liang X and Ma C: Tumor cell-intrinsic Tim-3 promotes liver cancer
via NF-κB/IL-6/STAT3 axis. Oncogene. 37:2456–2468. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maucort-Boulch D, de Martel C, Franceschi
S and Plummer M: Fraction and incidence of liver cancer
attributable to hepatitis B and C viruses worldwide. Int J Cancer.
142:2471–2477. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY,
Hu GY, Dong P, Bai FZ, Yan XL, Liao XZ, et al: Medical expenditure
for liver cancer in urban China: A 10-year multicenter
retrospective survey (2002–2011). J Cancer Res Ther. 14:163–170.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao SB, Li KL, Qiu H, Zhu LY, Pan CB, Zhao
Y, Wei SH, Shi S, Jin GH and Xue LX: Enhancing chemotherapy
sensitivity by targeting PcG via the ATM/p53 pathway. Am J Cancer
Res. 7:1874–1883. 2017.PubMed/NCBI
|
|
6
|
Laugesen A, Højfeldt JW and Helin K: Role
of the polycomb repressive complex 2 (PRC2) in transcriptional
regulation and cancer. Cold Spring Harb Perspect Med. 6:62016.
View Article : Google Scholar
|
|
7
|
Hu G, Gupta SK, Troska TP, Nair A and
Gupta M: Long non-coding RNA profile in mantle cell lymphoma
identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2
complex. Oncotarget. 8:80223–80234. 2017.PubMed/NCBI
|
|
8
|
Yoshida K, Toden S, Ravindranathan P, Han
H and Goel A: Curcumin sensitizes pancreatic cancer cells to
gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1
expression. Carcinogenesis. 38:1036–1046. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C,
Zhang Z, Wang YV, Huang L, Yuan M, et al: Phosphorylation of EZH2
by AMPK suppresses PRC2 methyltransferase activity and oncogenic
function. Mol Cell. 69:279–291.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smits M, Nilsson J, Mir SE, van der Stoop
PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J,
Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma
resulting in EZH2-induced proliferation, migration, and
angiogenesis. Oncotarget. 1:710–720. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Naga Prasad SV, Gupta MK, Duan ZH,
Surampudi VS, Liu CG, Kotwal A, Moravec CS, Starling RC, Perez DM,
Sen S, et al: A unique microRNA profile in end-stage heart failure
indicates alterations in specific cardiovascular signaling
networks. PLoS One. 12:e01704562017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valery PC, Laversanne M, Clark PJ, Petrick
JL, McGlynn KA and Bray F: Projections of primary liver cancer to
2030 in 30 countries worldwide. Hepatology. 67:600–611. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fang CH, Lu CM, Huang YP, Li XF, Fan YF,
Yang J, Xiang N and Pan JH: Study on the application value of
digital medical technology in the operation on primary liver
cancer. Zhonghua Wai Ke Za Zhi. 47:523–526. 2009.(In Chinese).
PubMed/NCBI
|
|
15
|
Wong MC, Jiang JY, Goggins WB, Liang M,
Fang Y, Fung FD, Leung C, Wang HH, Wong GL, Wong VW, et al:
International incidence and mortality trends of liver cancer: a
global profile. Sci Rep. 7:458462017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thomson DW and Dinger ME: Endogenous
microRNA sponges: Evidence and controversy. Nat Rev Genet.
17:272–283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z
and Liu X: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell
proliferation through repression of mitogen-activated protein
kinase-kinase 3. BMC Cancer. 13:4692013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Q, Yang X, Duan W, Li C, Luo Y and Lu
S: miRNA-346 promotes proliferation, migration and invasion in
liver cancer. Oncol Lett. 14:3255–3260. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cardenas H, Zhao J, Vieth E, Nephew KP and
Matei D: EZH2 inhibition promotes epithelial-to-mesenchymal
transition in ovarian cancer cells. Oncotarget. 7:84453–84467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang D, Wang X, Zhuang C, Shi W, Liu M,
Tu Q, Zhang D and Hu L: Reciprocal negative feedback loop between
EZH2 and miR-101-1 contributes to miR-101 deregulation in
hepatocellular carcinoma. Oncol Rep. 35:1083–1090. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kottakis F, Polytarchou C, Foltopoulou P,
Sanidas I, Kampranis SC and Tsichlis PN: FGF-2 regulates cell
proliferation, migration, and angiogenesis through an
NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 43:285–298. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo C, Merz PR, Chen Y, Dickes E, Pscherer
A, Schadendorf D and Eichmüller SB: MiR-101 inhibits melanoma cell
invasion and proliferation by targeting MITF and EZH2. Cancer Lett.
341:240–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang JJ, Chen JT, Hua L, Yao KH and Wang
CY: miR-98 inhibits hepatocellular carcinoma cell proliferation via
targeting EZH2 and suppressing Wnt/β-catenin signaling pathway.
Biomed Pharmacother. 85:472–478. 2017. View Article : Google Scholar : PubMed/NCBI
|
